Some medical breakthroughs come from unexpected sources. The origins of new weight-loss drugs such as Ozempic—known in the industry as GLP-1s—can be traced back to 2005, when they were introduced as a treatment for diabetes. Two decades later, these drugs have seemingly burst onto the medical scene, gaining notoriety for their ability to help people lose weight and the potential implications for a variety of other business sectors.

This "Ozempic effect" serves as an important lesson for investors: Healthcare innovations often have a cascading impact on the economy and their portfolios. With the healthcare industry working overtime on the next big breakthrough, identifying future winners in the medical field will lead investors to new opportunities.

The Outthinking Investor gathered insights from experts in the healthcare space to dig deeper into the future of medical innovations and how consumer behavior could change with the rise of weight-loss drugs. Our guests in this episode are Daniel Matviyenko, Managing Director and Portfolio Manager for Jennison's healthcare strategies; Scott Swanson, Principal and Credit Analyst at PGIM Fixed Income; and Tim Dall, a health economist and Executive Director at GlobalData.

Is the dream turning sour in Scotland?